✦ LIBER ✦

Phase 1b study results of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy

✍ Scribed by Smith, David A.; Conkling, Paul; Richards, Donald A.; Flores, Maria Regina C.; Nemunaitis, John J.; Boyd, Thomas E.; Mita, Alain C.; de La Bourdonnaye, Guillaume; Wages, David; Bexon, Alice S.

Book ID: 119320892
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 53 KB
Volume: 77
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2012.05.076

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9148 Phase 1 study of the toll-like rece

9148 Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib (E) and bevacizumab (B) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)

✍ Smith, D.A.; Conkling, P.; Richards, D.; Alemany, C.; Boyd, T.; Garbo, L.; Wu, H 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Antitumor activity and safety of combina

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

✍ Smith, David A.; Conkling, Paul; Richards, Donald A.; Nemunaitis, John J.; Boyd, 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 287 KB